HT1080-Fluc-Neo/iRFP-Puro is a polyclonal population of the human fibrosarcoma cell line HT1080  (ATCC® CCL-121™). To achieve stable reporter expression in the polyclonal population, parental HT1080 cells were transduced with LV-Fluc-P2A-Neo (LV011) and LV-iRFP-P2A-Puro (LV032) and selected using G418 and puromycin. LV-Fluc-P2A-Neo encodes the firefly luciferase (Fluc) cDNA linked to the neomycin resistance gene (Neo) via a P2A cleavage peptide under the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes the near-infrared fluorescent protein (iRFP) cDNA linked to the puromycin resistance gene (Puro) via P2A under the SFFV promoter.

*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

This cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

The parental HT1080 cell line has been authenticated and certified free of interspecies cross contamination by short tandem repeat (STR) profiling with 9 STR loci.

Replication Competent Lentivirus (RCL) Test (including a test report) is available for this cell line at an added cost.  Contact us to learn more.

Morphology

Low and high density cell morphology (200x)

iRFP Expression

HT1080-Fluc-Neo/iRFP-Puro (red) or control (HT1080-Fluc-Puro) cells were fixed with paraformaldehyde and analyzed by flow cytometry (20,000 events).

Luciferase Expression

10⁴, 10⁵, or 10⁶ cells were placed in wells of a 96-well plate and 0.3 mg of d-luciferin was added to the indicated wells. The plate was immediately imaged using a Xenogen IVIS Spectrum.

In Vivo Imaging

HT1080-Fluc-Puro cells (Imanis Life catalog #CL076) were injected subcutaneously into the right flanks of female NCR athymic mice. Mice were imaged at day 0 on the day of cell implantation and subsequently at days 7 and 16 using a Perkin Elmer IVIS® Spectrum system, at 10-15 minutes post intraperitoneal injection of D-luciferin at 150 mg/kg. Tumor size was measured using calipers. Data from a representative mouse (ID#6329) is shown.

Complete Growth Medium: DMEM supplemented with 10% FBS, 1X Penicillin/Streptomycin, 1.25 mg/mL G418, and 1 µg/mL puromycin.

The addition of G418 and puromycin to the complete growth medium maintains high dual reporter expression over continued passage of the cells. It is highly recommended, especially if the cells undergo multiple passages prior to being used for studies.

These cells should be grown in the indicated medium and passaged when they reach confluency. For routine passaging, cells are recommended to be split at a 1:10 ratio every 3-4 days.

These cells are suitable for in vitro and in vivo experimentation.

HT1080 cells are a xenograph model for fibrosarcoma and form primary tumors and distant metastases (lung, liver, and brain) post implantation into immunosuppressed mice.^1,2

The Fluc and iRFP transgenes facilitate noninvasive bioluminescence and in vivo and ex vivo fluorescence imaging, respectively, of implanted cells. To reduce background autofluorescence, mice should be fed an alfalfa-free diet for at least a week prior to imaging.

The cells can be amplified in vitro and used to generate additional frozen stocks. Cryopreservation of low passage stocks is recommended. Frozen stocks should be preserved in a designated cryopreservation medium.

These cells were generated via lentiviral vector transduction. The lentiviral vector used for transduction was a self-inactivating (SIN) vector in which the viral enhancer and promoter have been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR³. Nevertheless, all work with these cells should be performed under biosafety-level 2 (BSL2) conditions by trained personnel. Institutional requirements may permit handling of these cells under BSL1 conditions if certain criteria are met.

References:
¹Rasheed et al. Cancer. 1974. 33:1027-1033.
²Praus et al. Gene Therapy. 1999. 6:227-236.
³Miyoshi et al. J Virol 1998. 72:8150-8157.